Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

被引:524
作者
Lipshultz, SE
Lipsitz, SR
Sallan, SE
Dalton, VM
Mone, SM
Gelber, RD
Colan, SD
机构
[1] Univ Miami, Holtz Childrens Hosp, Miller Sch Med, Dept Pediat, Miami, FL 33101 USA
[2] Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Harvard Univ, Sch Med, Dept Pediat Oncol, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Div Hematol Oncol, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA
[7] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA
[8] Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA
关键词
D O I
10.1200/JCO.2005.12.121
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Cross-sectional studies show that cardiac abnormalities are common in long-term survivors of doxorubicin-treated childhood malignancies. Longitudinal data, however, are rare. Methods Serial echocardiograms (N = 499) were obtained from 115 doxorubicin-treated long-term survivors of childhood acute lymphoblastic leukemia (median age at diagnosis, 4.8 years; median follow-up after completion of doxorubicin, 11.8 years). Results were expressed as z scores to indicate the number of standard deviations (SDs) above (+) or below (-) the normal predicted value. Median individual and cumulative doxorubicin doses were 30 mg/m per dose and 352 mg/m(2), respectively. Results Left ventricular fractional shortening was significantly reduced after doxorubicin therapy, and the reduction was related to cumulative dose. z scores for fractional shortening transiently improved before failing to -2.76 more than 12 years after diagnosis. Reduced fractional shortening was related to impaired contractility and increasing afterload, consequences of a progressive reduction of ventricular mass, and wall thickness relative to body-surface area. Left ventricular contractility fell significantly over time and was depressed at last follow-up in patients receiving more than 300 mg/m(2) of doxorubicin. Systolic and diastolic blood pressures were below normal more than 9 years after diagnosis. Even patients receiving lower cumulative doxorubicin doses experienced reduced mass and dimension. Fractional shortening and dimension at the end of therapy predicted these parameters 11.8 years later. Conclusion Cardiac abnormalities were persistent and progressive after doxorubicin therapy. Inadequate ventricular mass with chronic afterload excess was associated with progressive contractile deficit and possibly reduced cardiac output and restrictive cardiomyopathy. The deficits were worst after highest cumulative doses of doxorubicin, but appeared even after low doses.
引用
收藏
页码:2629 / 2636
页数:8
相关论文
共 40 条
[31]  
Nakamura T, 2000, CIRCULATION, V102, P572
[32]   Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia [J].
Nysom, K ;
Holm, K ;
Lipsitz, SR ;
Mone, SM ;
Colan, SD ;
Orav, EJ ;
Sallan, SE ;
Olsen, JH ;
Hertz, H ;
Jacobsen, JR ;
Lipshultz, SE .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :545-550
[33]   Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children [J].
Poutanen, T ;
Tikanoja, T ;
Riikonen, P ;
Silvast, A ;
Perkkiö, M .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2349-2356
[34]  
Ries L. A. G., 1999, Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995
[35]   EFFICACY AND SAFETY OF METOPROLOL IN THE TREATMENT OF DOXORUBICIN-INDUCED CARDIOMYOPATHY IN PEDIATRIC-PATIENTS [J].
SHADDY, RE ;
OLSEN, SL ;
BRISTOW, MR ;
TAYLOR, DO ;
BULLOCK, EA ;
TANI, LY ;
RENLUND, DG .
AMERICAN HEART JOURNAL, 1995, 129 (01) :197-199
[36]   Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995) [J].
Silverman, LB ;
Declerck, L ;
Gelber, RD ;
Dalton, VK ;
Asselin, BL ;
Barr, RD ;
Clavell, LA ;
Hurwitz, CA ;
Moghrabi, A ;
Samson, Y ;
Schorin, MA ;
Lipton, JM ;
Cohen, HJ ;
Sallan, SE .
LEUKEMIA, 2000, 14 (12) :2247-2256
[37]   Cardiomyopathy caused by antineoplastic therapies [J].
Valeriano C. Simbre ;
M. Jacob Adams ;
Sampada S. Deshpande ;
Sarah A. Duffy ;
Tracie L. Miller ;
Steven E. Lipshultz .
Current Treatment Options in Cardiovascular Medicine, 2001, 3 (6) :493-505
[38]   Late anthracycline cardiotoxicity after childhood cancer - A prospective longitudinal study [J].
Sorensen, K ;
Levitt, GA ;
Bull, C ;
Dorup, I ;
Sullivan, ID .
CANCER, 2003, 97 (08) :1991-1998
[39]  
*US NAT CANC I WOR, 2002, WORKSH PED ONC LAT E
[40]  
Zhou SY, 2001, CANCER RES, V61, P771